BPC 157 Review: Doctor Explains Benefits, Safety & Cancer Risk Peptides in the Limelight: US FDA May Ease Restrictions on Several Peptides The Dermatology Digest BREAKING: FDA UPDATES CATEGORY 2 BULKS LIST OFFICIALLY REMOVES PEPTIDES LIKE BPC 157 The first opportunity for reclassification comes on July 23 24 during the FDA's PCAC meeting Until then, peptides are BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with Peptide power laws Chief Longevity Officer